Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multi-Centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide.

NCT02922218 is registered in ClinicalTrials.gov with Centro Nacional de Investigaciones Oncologicas CARLOS III as lead sponsor.

NCT NCT02922218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02922218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multi-Centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide.
Lead sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2016
Completion date
December 31, 2020
Enrollment
187 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer, castration resistant, enzalutamide